New approaches aim to extend treatment durability and improve long-term vision outcomes in wet AMD. Scientific American Custom Media recently sat down with Dr. Nadia Waheed, Ocular Therapeutix’s chief medical officer, to discuss the real-world burden behind the standard of care and how emerging approaches, including sustained-delivery therapies under investigation, aim to reduce it. This podcast was produced for Ocular Therapeutix by Scientific American Custom Media, a division separate from the magazine’s board of editors.Learn more about your ad choices. Visit megaphone.fm/adchoicesLearn more about your ad choices. Visit megaphone.fm/adchoices